Quarterly report pursuant to Section 13 or 15(d)

Business (Tables)

v3.21.1
Business (Tables)
9 Months Ended
Mar. 31, 2021
Schedule Of Entities In Control [Abstract]  
Summary of entities in control
The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries:
 
    
Principal place of

business/country of

incorporation
  
Ownership
Fiscal Year
2020
   
Ownership
Fiscal Year
2019
 
Benitec Biopharma Proprietary Limited (“BBL”)
   Australia      100 %     —    
Benitec Australia Proprietary Limited
   Australia      100 %     100 %
Benitec Limited
   United Kingdom      100 %     100 %
Benitec, Inc.
   USA      100 %     100 %
Benitec LLC
   USA      100 %     100 %
RNAi Therapeutics, Inc.
   USA      100 %     100 %
Tacere Therapeutics, Inc.
   USA      100 %     100 %